Introduction
human neutrophils and selectively blocks LTB 4 -induced activation events in neutrophils including: calcium mobilization, superoxide generation, homotypic aggLeukotriene B 4 (LTB 4 ) is a pro-inflammatory, naturally occurring eicosanoid mediator that has been implicated regation, chemiluminescence and upregulation of Macrophage-1 antigen (Mac-1) [6] [7] [8] . Furthermore, it in a variety of human inflammatory diseases [1] [2] [3] [4] [5] .
LY293111 (2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-
has been shown that incubation of LY293111 with whole human blood inhibits LTB 4 -induced Mac-1 5-hydroxyphenoxy] propoxy] phenoxy]benzoic acid) is a potent and selective receptor antagonist for LTB 4 upregulation on neutrophils in situ [7] .
Mac-1 is a heterodimeric cell surface adhesion (Figure 1 ). Previous studies have shown that LY293111 competitively inhibits binding of [3H]−LTB 4
to isolated molecule belonging to the integrin superfamily [9, 10] .
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Study design
The study was subdivided into three distinct periods, differentiated by the dosage and frequency of LY293111 that was orally administered. In all three periods, subjects were randomized and administered either LY293111 or placebo in a double-blinded manner. In the first period, volunteers received either 60 mg LY293111 or placebo three times daily for 7 days with a final, single dose on day 8 (22 total doses). Blood samples were collected on day 1, immediately prior to It is composed of an a m and b 2 chain and can be the first dose (pre-dose control) and prior to the 4th immunologically identified by its reactivity with mono-(day 2 ) and 22nd doses (day 8 ). Additional blood clonal antibodies (MAb) specific to the cluster desigsamples were obtained on days 10, 12, and 14, in order nations (CD) CD11b and CD18.
to monitor the duration of any effects. All blood samples Cell surface membrane expression of Mac-1 on were challenged ex vivo with LTB 4 to study upregulation neutrophils is upregulated in response to various of cell surface Mac-1 on circulating neutrophils (see agonists including N-formyl-methionyl-leucyl-phenyldetailed procedure below). alanine (fMLP) and LTB 4 . This upregulation of Mac-1 The second period was designed similarly to the first is closely associated with an increase in neutrophil except that subjects received either 120 mg LY293111 adhesion as indicated in both in vitro studies and in or placebo three times daily. Blood was drawn at the animal models of inflammatory diseases [11] [12] [13] .
same intervals as in the first period and again challenged In this, the first human dose studies with LY293111, with LTB 4 ex vivo. In addition, each blood sample was we measured Mac-1 upregulation on neutrophils taken also challenged ex vivo with buffer in order to determine from subjects receiving the compound orally. The aim the basal or non-activated CD11b expression levels of of this study centred on collection of these Mac-1 data the collected neutrophils. for use in defining the extent and duration of LY293111's
In the third period, volunteers received either 200 mg in vivo bioactivity on target cells likely to be involved LY293111 or placebo twice daily for 7 days with a final in various inflammatory diseases.
dose on day 8 (15 total doses). Blood was collected immediately prior to the first (pre-dose control), third (day 2 ), and 15th (day 8) dose. Additional blood samples were taken 2 h after the 15th dose (day 8 ) and on days Methods 10, 12 and 14. In this period, each blood sample was treated with either LTB 4 , buffer or with N-formylSubjects methionyl-leucyl-phenylalanine (fMLP) to measure the selectivity of drug action. A total of 24 healthy male subjects, ranging in age from 18 to 42 years, and weighing between 57 and 88 kg participated in this study. The study protocol was Ex vivo Mac-1 assay approved by the Simbec Independent Ethics Committee (Simbec Research Ltd, Merthyr Tydfil Industrial Park, A previously described procedure for stimulating and Mid-Glamorgan, UK). Subjects were enrolled into the measuring Mac-1 up-regulation on plasma membrane study after they had been given a full explanation of all surfaces of human neutrophils was utilized without procedures and had given written consent to participate. appreciable modification [ 7, 14] . Briefly summarized, 5 ml venous blood was collected from subjects into evacuated blood collection tubes containing EDTA as the anticoagulant. Sample processing commenced within Drug 2 h of collection. The buffer used throughout processing was Hanks' Balanced Salt Solution (BioWhittaker, The chemical nomenclature (USAN) for LY293111 ( Figure 1 ) Samples were then rapidly cooled on ice and further incubated with 10 ml of an anti-Mac-1 antibody, coupled crystalline cellulose ranged from 18 to 24% and the pregelatinized starch from 60 to 73%. Matching capsules to fluorescein (Mo-1-FITC, Coulter Corp., Hialeah, FL, USA) for an additional 30 min at 4°C. To allow for containing these inactive ingredients were used for placebo administration.
quantitative immunofluorescence comparisons, the same manufacturer's lot of antibody was used for all samples in %), relative to their respective pre-dosing values. In the case of placebo subject D3 from the 60 mg period processed in the study. After antibody incubation, the residing red blood cells were lysed with 2.0 ml FACSB (Table 1 ) , the pre-dose response was conspicuously low (MFI=55), and seriously distorted the average of ratios Lysing Solution (Becton Dickinson, San Jose CA, USA) and the resultant white blood cells fixed in a 1% (w/v) for the placebo group. Consequently, an accommodation technique was applied that simply replaced the original paraformaldehyde (Polysciences, Inc., Warrington, PA, USA) solution dissolved in phosphate buffered saline. value with the average over all days (81 ), since responses were quite stable after the original measurement Processed and fixed samples were stored in the dark at 4°C and analysed within 1 week of collection using a (86.4±4.2 s.d.).
A split-plot analysis of variance (ANOVA) for a previously described flow cytometric technique [7, 14 ] . For each sample, the mean fluorescence intensity (MFI) repeated-measures design was conducted which incorporated dose groups (0, 60, 120, and 200 mg) and of at least 5000 light scatter-gated neutrophils was determined using a Profile II flow cytometer(Coulter measurement days (2, 8, 10, 12 , and 14 ) as fixed factors. Subjects within dose groups served as the whole-plot Electronics, Inc., Hialeah FL, USA).
error with the residual as the subplot error. A posteriori comparisons were made within the ANOVA model through pairwise contrasts. A value of P≤0.05 (twoStatistical analysis tailed) was considered as nominally significant. Due to the multiplicity of statistical tests performed, caution To determine the effect of orally administered LY293111 on ex vivo neutrophil Mac-1 upregulation, the pre-dose needs to be taken in interpreting statistical significance. With missing observations (9%) in the data, least-square blood sample was utilized to determine the baseline response for each subject. LTB 4 and fMLP-stimulated means are tested and reported in the statistical analyses. The statistical software package SASB (SAS Institute, Mac-1 determinations were made in duplicate and averaged. The net stimulated MFI values were deterCary NC, USA) was used in all tests and computations. mined by subtracting the basal ( buffer-treated) Mac-1 value. Since basal levels were not determined in the 60 mg period, exogenous data sources were used to furnish an average basal value. A mean (±s.e. mean) Results basal value was computed from the placebo-treated subjects in the 120 and 200 mg groups (MFI=39±2, 60 mg period n=26 ) and utilized for the 60 mg period's data analysis.
Calculations of net MFI that lead to negative values
The effect of LY293111 administered at 60 mg three times daily on ex vivo neutrophil Mac-1 upregulation is were truncated to 0. Hence, the net MFIs of the 60 mg period can be considered approximations, and condisplayed in Table 1 and summarized in Table 4 and Figure 2 . Subject D6 dropped out of the study prior to clusions drawn from these data should be tempered with the recognition that the responses could be biased.
receiving all 22 doses of LY293111 for reasons that were independent of any study issues. All subjects receiving The net MFI values were converted to ratios (expressed LY293111 displayed inhibited Mac-1 responses by the first measurement period after receiving the drug ( Table 1 ). The average ratio for this time period was 31% (of pre-dose values) and was computed to be a statistically significant (P<0.01) inhibition. The inhibitory effect was maximum on day 8 and gradually waned after the cessation of dosing (Figure 2 ). No suppression of Mac-1 responses were observed in the placebo-dosed (D3 and D7) subjects (Table 1 ) .
mg period
A similar inhibitory profile was observed for subjects receiving the 120 mg dose of LY293111. As observed in the 60 mg period, all subjects receiving LY293111 displayed inhibited Mac-1 responses by the first measurement period after receiving drug. This first measurement point (day 2 ) was in fact the period of maximum inhibition for this period (Figure 3 ). The Mac-1 response remained significantly suppressed Responses from placebo-treated blood samples ( Table 2, 200 mg LY293111 three times daily orally and whole blood subject D10) were virtually unchanged from prewas collected and challenged ex vivo with LTB 4 ($) or dose levels. of subjects receiving 200 mg LY293111, twice daily were a22 oral doses of LY293111 ( 120 mg) or placebo; bpre-dose period; cmean fluorescence intensity (MFI) of at least 5000 light scatter-gated neutrophils; dLTB 4 -stimulated samples processed and measured in duplicate; esample not analysed.
significantly inhibited in their ability to respond to an in significantly (P<0.01) inhibited LTB 4 -stimulated responses as compared with both pre-dose levels and LTB 4 challenge but not inhibited in their response to fMLP, an alternate neutrophil agonist. As observed in placebo-treated controls (Table 5 ) . Although some differences in daily effects were observed for the three the other periods (60 mg and 120 mg), the response to LTB 4 was once again significantly depressed by the first dosing regimens (Table 4 ) , the treatment protocols were not significantly different in their average effects with sampling period (day 2) and remained suppressed through day 8. For this period, an additional blood respect to LTB 4 induced Mac-1 upregulation (Table 6 ). sample was taken 2 h after the final dose (day 8). This sample yielded the maximum point of inhibition of the LTB 4 -challenged responses (Figure 4 ) . No suppression of the fMLP-induced responses were observed, throughDiscussion out the sampling periods of this segment. Furthermore, subjects receiving placebo (Table 3 , subjects D19 and A role for LTB 4 in inflammatory disease has been suggested for some time [1] [2] [3] [4] [5] [15] [16] [17] [18] [19] [20] [21] . The evidence for D24) did not display suppressed responses to either LTB 4 or fMLP. its importance in inflammation has led to the development of several potent and selective receptor antagonists [22] . While many of these potential drugs have been evaluated in in vitro systems, only a few of them have Comparison of treatment effects been evaluated in humans [ 23] . In this manuscript, we present data collected during the first clinical study of The average effects on LTB 4
-stimulated Mac-1 responses (post dose) over the course of the studies are displayed LY293111 in humans.
The study described in this manuscript was primarily in Table 5 . All three treatment protocols resulted designed as a safety study. With this in mind, all no significant toxic events were noted for any subject at any dose administered. measures appropriate to such a study were undertaken including the measurement of plasma drug levels and
The novel aspect of this study was the ability to measure LY293111's pharmacological activity in a profiles of the subjects' well being. It should be noted (data not shown) that the results of this study indicated study designed primarily for safety evaluations. We accomplished this by measuring the levels of Mac-1 that LY293111 was present in the subject's plasma and adhesion molecules on neutrophils in small blood ately (during the first sampling period) after dosing. LTB 4 -induced neutrophil activation remained inhibited samples taken throughout each period. The data indicate that LY293111 is orally absorbed in humans and has a throughout the dosing periods and gradually returned to pre-dose levels 2-6 days after the cessation of dosing. pharmacological effect on blood neutrophils. The neutrophils from LY293111-treated subjects were selectively Neutrophils were not blocked in their response to fMLP, indicating a selectivity of the pharmacological inhibited in their ability to react to exogenous LTB 4 . Three doses (60, 120, 200 mg) of LY293111 were effect. Although there were slight differences in activity of the doses on specific days, no statistically significant evaluated in this study. All were effective in producing the Mac-1 inhibitory effect. There were no inhibitory differences were apparent when the dose regimens were evaluated in total. Among possible explanations for this effects of placebo observed in this study. It should be noted that all subjects that received LY293111 displayed lack of dose/action differentiation might be that all three doses were above the threshold for producing the an LTB 4 -specific blockade of neutrophil activation. Furthermore, this inhibitory effect was observed immedimaximal inhibitory effect and only doses below those
